Table 1
Receptor changes in Huntington's disease6
| Decreased | Increased | ||
|---|---|---|---|
| Receptor | Regions | Receptor | Region |
| CN, caudate nucleus; GPE, globus pallidus externum; GPI, globus pallidus internum; P, putamen; SN, substantia nigra. | |||
| Early clinical phase | |||
| Cannabinoid CB (1) | CN, P, GPE | GABA (A) | GPE |
| Dopamine D2 | CN, P, GPE | ||
| Adenosine A (2a) | CN, P, GPE | ||
| Intermediate clinical phases | |||
| Cannabinoid CB (1) | CN, P, SN | ||
| Dopamine D1 | CN, P, SN | ||
| Final clinical phase | |||
| Cannabinoid CB (1) | CN, P, GPI | GABA (A) | GPI |
| Dopamine D1 | CN, P, GPI | ||
